NRG1 News

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Cholangiocarcinoma

07/08/2026

Stephanie Holland

Results from the phase 2 eNRGy trial demonstrated that zenocutuzumab produced durable clinical activity with a favorable safety profile in patients with advanced NRG1 fusion-positive cholangiocarcinoma, supporting HER2/HER3-targeted therapy...

Results from the phase 2 eNRGy...

07/08/2026

Oncology

News

Zenocutuzumab Demonstrates Durable Efficacy for Patients With NRG1-Positive Cholangiocarcinoma

12/02/2025

Stephanie Holland

According to updated results from the ongoing, phase 2 eNRGy trial, zenocutuzumab demonstrated durable efficacy and safety among patients with NRG1-positive cholangiocarcinoma.

According to updated results...

12/02/2025

Oncology

News

FDA Grants Breakthrough Therapy Designation to Zenocutuzumab for Patients With Advanced NRG1-Positive Cholangiocarcinoma

10/30/2025

Stephanie Holland

Based on updated results from the phase 2 eNRGy trial, the FDA has granted Breakthrough Therapy designation to zenocutuzumab for the treatment of patients with advanced unresectable or metastatic NRG1-positive cholangiocarcinoma.

Based on updated results from...

10/30/2025

Oncology

News

The Distinct Gene Landscape of Neuregulin 1 Fusions

09/30/2025

Allison Casey

According to a retrospective study, patients with NRG1 fusions have distinct genetic and molecular characteristics.

According to a retrospective...

09/30/2025

Oncology

News

Neuregulin 1 Variants of Uncertain Significance Associated With Poor Prognosis in Advanced Non-Small Cell Lung Cancer

09/18/2025

Allison Casey

According to a retrospective analysis, neuregulin 1 variants of uncertain significance were associated with poor prognosis, and other oncogene alterations, in advanced non-small cell lung cancer.

According to a retrospective...

09/18/2025

Oncology

News

NRG1 May Predict Incidence of CRPC Among Patients With Prostate Cancer

08/05/2025

Allison Casey

NRG1 levels prior to ADT may assist in predicting castration-resistant prostate cancer among patients with prostate cancer receiving ADT.

NRG1 levels prior to ADT may...

08/05/2025

Oncology

News

Potential Therapeutic Targets for Patients With Invasive Mucinous Adenocarcinoma

07/24/2025

Allison Casey

A recent study found invasive mucinous adenocarcinomas have a higher likelihood of harboring KRAS mutations and NRG fusion genes.

A recent study found invasive...

07/24/2025

Oncology

News

Potential Activity of Afatinib Among Patients With Advanced Solid Tumors With NGR1 Fusions

05/06/2025

Allison Casey

According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.

According to a case series of...

05/06/2025

Oncology

News

The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma

04/10/2025

Allison Casey

Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.

Targeting NRG1 may present a...

04/10/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

Recent News

News

NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera

09/22/2026

Stephanie Holland

Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...

Updated NCCN Guidelines...

09/22/2026

Oncology

News

FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes

09/22/2026

Emily Estrada

The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...

The FDA granted Fast Track...

09/22/2026

Oncology

News

Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer

09/22/2026

Stephanie Holland

Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...

Results from the phase 3...

09/22/2026

Oncology

News

Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma

09/21/2026

Emily Estrada

Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...

Results from the phase 3...

09/21/2026

Oncology

FDA Approval

FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer

09/18/2026

Stephanie Holland

Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...

Based on results from the phase...

09/18/2026

Oncology

FDA Alerts

FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer

09/17/2026

Emily Estrada

The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...

The FDA approved a supplemental...

09/17/2026

Oncology

News

Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma

09/17/2026

Emily Estrada

Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...

Results from the phase 3 EPCORE...

09/17/2026

Oncology

News

Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation

09/17/2026

Emily Estrada

Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...

Results from a phase 3 trial...

09/17/2026

Oncology

News

Sacituzumab Govitecan Plus Pembrolizumab Fails to Significantly Improve PFS in PD-L1–High Metastatic Non-Small Cell Lung Cancer

09/16/2026

Stephanie Holland

Results from the phase 3 EVOKE-03 trial demonstrated that adding sacituzumab govitecan to pembrolizumab did not significantly improve progression-free or overall survival in untreated patients with PD-L1–high metastatic non-small cell lung...

Results from the phase 3...

09/16/2026

Oncology

FDA Alerts

FDA Label Update Shortens Initial Tarlatamab Monitoring to Support Broader Extensive-Stage Small Cell Lung Cancer Treatment Access

09/16/2026

Stephanie Holland

The FDA updated the prescribing information for tarlatamab to substantially shorten monitoring following the first 2 doses in patients with extensive-stage small cell lung cancer, potentially reducing treatment burden and facilitating...

The FDA updated the prescribing...

09/16/2026

Oncology